|
|
Core Support for Cancer Center
|
2P30CA013330-40
|
$3,589,611
|
$107,688
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Core Support for Cancer Center
|
3P30CA013330-40S1
|
$75,000
|
$2,250
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Deciphering the Tissue Specificity of MEN1 Related Tumorigenesis
|
5R01CA170911-02
|
$325,734
|
$162,867
|
Libutti, Steven
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
|
5R01CA163907-02
|
$326,417
|
$326,417
|
SCHWARTZ, EDWARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
|
Community Clinical Oncology Program
|
5U10CA037422-26
|
$2,811,894
|
$56,238
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-37
|
$14,566,378
|
$582,655
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RTOG Biospecimen Repository
|
5U24CA114734-08
|
$977,658
|
$97,766
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
American College of Radiology Imaging Network
|
3U10CA080098-14S2
|
$5,146,722
|
$205,869
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Mutation-Specific p53 Antibodies as Biomarkers of Pancreatic Cancer
|
5R21CA164593-02
|
$155,627
|
$155,627
|
Anderson, Karen
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Advanced Glycation End-Products and Risk of Pancreatic Cancer
|
1R01CA172880-01A1
|
$524,349
|
$524,349
|
JIAO, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-07S1
|
$75,000
|
$2,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-07S2
|
$43,265
|
$1,298
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-07
|
$3,092,811
|
$92,784
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-29
|
$612,504
|
$6,125
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
The Co-Clinical Trial Project
|
5U01CA141457-05
|
$695,315
|
$229,454
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
EndoPulse System for Endoscopic Ultrasound-Guided Therapy of Pancreatic Carcinoma
|
5R44CA150484-03
|
$1,141,554
|
$1,141,554
|
NUCCITELLI, RICHARD
|
BIOELECTROMED CORPORATION
|
|
|
SBIR Phase II: Low-Cost Microfluidic System for Detection of CTC's.
|
N44CO130071-000
|
$999,873
|
$999,873
|
HUPERT, MATEUSZ
|
BIOFLUIDICA MICROTECHNOLOGIES LLC
|
|
|
Pre-clinical development of a novel pancreatic cancer chemotherapeutic
|
1R43CA180398-01
|
$289,518
|
$289,518
|
Chan, Kyle
|
BIOTHERYX, INC.
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S3
|
$501,282
|
$5,013
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S4
|
$122,789
|
$1,228
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
Non-Oncogene Addiction as a Targeted Therapy for Pancreatic Cancer
|
1R21CA164245-01A1
|
$178,024
|
$178,024
|
Faller, Douglas
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Defining lineage-specific determinants of K-Ras "addiction" in human cancers
|
5R00CA149169-04
|
$229,718
|
$75,807
|
SINGH, ANURAG
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
ACOSOG Competing Renewal
|
5U10CA076001-17
|
$2,940,780
|
$235,262
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Support for Specimen Banking in ACOSOG
|
5U24CA114736-08
|
$737,524
|
$147,505
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Biostatistics Data Management Center for ACRIN
|
3U10CA079778-14S1
|
$2,271,308
|
$90,852
|
Gatsonis, Constantine
|
BROWN UNIVERSITY
|
|
|
Microbiomes in Human Pancreatic Cancer
|
1R01CA166150-01A1
|
$713,133
|
$713,133
|
MICHAUD, DOMINIQUE
|
BROWN UNIVERSITY
|
|
|
Testing of novel anti-cancer compounds Curaxins against pancreatic cancer
|
3R41CA159657-01A1S1
|
$179,664
|
$179,664
|
GUROVA, KATERINA
|
BUFFALO BIOLABS, LLC
|
|
|
Carle Cancer Center Community Clinical Oncology Program
|
2U10CA035195-30
|
$828,213
|
$8,282
|
ROWLAND, KENDRITH
|
CARLE FOUNDATION
|
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
3U01CA062502-19S1
|
$841,154
|
$8,412
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-23
|
$4,740,480
|
$189,619
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-23S2
|
$37,026
|
$1,481
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
A RAS-FAM83A Regulatory Loop as a Novel Therapeutic Target for Pancreatic Cancer
|
1R21CA178651-01
|
$206,843
|
$206,843
|
Jackson, Mark
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Targeting Telomerase in Pancreateic Cancer
|
1R21CA169611-01A1
|
$217,425
|
$217,425
|
Taylor, Derek
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Next-generation mouse gene-targeting technology to model tumorigenesis
|
1R21CA181859-01
|
$241,316
|
$79,634
|
Wang, Zhenghe
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Improving Pancreas RT Plans using Respiration-driven Anatomic Deformation
|
1R03CA173273-01
|
$80,063
|
$80,063
|
Yang, Wensha
|
CEDARS-SINAI MEDICAL CENTER
|
|
|
Research and Mentoring on Energetic Factors and Cancer: Established Investigator
|
5K05CA136967-05
|
$139,821
|
$6,991
|
BERNSTEIN, LESLIE
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC
|
1R21CA174306-01A1
|
$182,700
|
$182,700
|
Diamond, Don
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Cancer Center Support Grant
|
2P30CA033572-30
|
$2,042,489
|
$20,425
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-30S1
|
$125,000
|
$1,250
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-30S2
|
$52,354
|
$524
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-30S3
|
$10,680
|
$107
|
FRIEDMAN, MICHAEL
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
|
Development of Monoclonal Antibodies To Treat Pancreatic Cancer
|
1R43CA174025-01A1
|
$220,099
|
$220,099
|
Pantazis, Panayotis
|
COARE BIOTECHNOLOGY, INC.
|
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
5P01CA013106-42
|
$4,101,060
|
$205,053
|
Hannon, Gregory
|
COLD SPRING HARBOR LABORATORY
|
|
|
CSHL CANCER CENTER SUPPORT GRANT
|
5P30CA045508-26
|
$4,077,038
|
$122,311
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
|
Chemical genetic profiling of engineered tumor cells
|
2R01CA097061-10A1
|
$350,176
|
$350,176
|
STOCKWELL, BRENT
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
|
Genetic and pharmacological manipulation of system xc in pancreatic cancer
|
1F31CA180738-01
|
$42,232
|
$42,232
|
Badgley, Michael
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-39S3
|
$3,546,194
|
$141,848
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-39S4
|
$75,000
|
$3,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-39S5
|
$125,000
|
$5,000
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Cancer Center Support Grant
|
3P30CA013696-39S6
|
$49,718
|
$1,989
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Total relevant funding to Pancreas for this search: $101,936,107
|
